Release details

2015-12-22 07:20 CET
  • Print
  • Share Share
en

Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension

Dear member of the investment community

Actelion announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH).

An investor conference call & webcast will be held to discuss the approval at 14:00hrs on 05 January 2016.

Date/Time:

     
05 January 2016 14:00hrs - 15:00hrs Basel (CET)
  13:00hrs - 14:00hrs UK (GMT)
  8:00 a.m. - 9:00 a.m. US (EST)

Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.  

       
Dial: Europe: +41 (0)44 583 18 01
  UK: +44 203 194 0561
  US: +1 646 722 4897
           

Webcast Access:
Webcast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.

Participant's mode: Listen-Only

Webcast Replay:
The archived Investor Webcast will be available for replay through www.actelion.com approximately 60 minutes after the call has ended.

Press release
Dec 22, 2015

HUG#1975273